|
|
Article: Intensified Competition in Severe Fungal Infections Drug Market.
- Article from:
- BIOTECH Patent News
- Article date:
- November 1, 2008
CopyrightCOPYRIGHT 2008 Biotech Patent News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Decision Resources (Waltham, MA), one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, said that, because of their improvements in safety and efficacy, physicians are increasingly prescribing next-generation antifungals such as Pfizer's Vfend, Schering-Plough's Noxafil, Merck's Cancidas, Astellas' Mycamine and Pfizer's Eraxis. Following the recent launches of several next-generation azoles (such as Vfend and Noxafil) and echinocandins (such as Cancidas, Mycamine and Eraxis), the severe fungal infections market has become increasingly competitive.
The new Pharmacor report entitled "Severe Fungal Infections" finds that ...